Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month High – Here’s What Happened

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) hit a new 52-week high on Wednesday . The company traded as high as $49.33 and last traded at $48.07, with a volume of 55405 shares traded. The stock had previously closed at $48.15.

Wall Street Analyst Weigh In

KNSA has been the subject of a number of recent research reports. Wedbush upped their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Canaccord Genuity Group initiated coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They issued a “buy” rating and a $62.00 price objective for the company. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $55.29.

Kiniksa Pharmaceuticals International Stock Performance

The company has a fifty day simple moving average of $45.15 and a 200 day simple moving average of $41.67. The stock has a market capitalization of $3.70 billion, a price-to-earnings ratio of 65.43 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The company had revenue of $202.13 million during the quarter, compared to analyst estimates of $200.86 million. During the same period in the previous year, the company posted ($0.12) EPS. The company’s quarterly revenue was up 65.0% on a year-over-year basis. As a group, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, CFO Mark Ragosa sold 17,845 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $43.28, for a total transaction of $772,331.60. Following the completion of the sale, the chief financial officer owned 12,086 shares of the company’s stock, valued at approximately $523,082.08. This represents a 59.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Barry D. Quart sold 2,690 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $45.00, for a total transaction of $121,050.00. Following the transaction, the director owned 12,546 shares of the company’s stock, valued at approximately $564,570. The trade was a 17.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 48,605 shares of company stock valued at $2,122,646 in the last three months. Insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently bought and sold shares of KNSA. Amundi acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth about $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Kiniksa Pharmaceuticals International by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after purchasing an additional 1,002 shares during the period. Millennium Management LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares in the last quarter. Creative Planning acquired a new stake in Kiniksa Pharmaceuticals International during the second quarter worth approximately $358,000. Finally, Franklin Resources Inc. grew its stake in Kiniksa Pharmaceuticals International by 62.2% during the second quarter. Franklin Resources Inc. now owns 108,574 shares of the company’s stock worth $3,004,000 after purchasing an additional 41,632 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.